Friederike Sixel-Döring1,2, Johannes Zimmermann3, Andrea Wegener1, Brit Mollenhauer1,4,5, Claudia Trenkwalder1,4. 1. Paracelsus-Elena-Klinik, Kassel, Germany. 2. Department of Neurology, Philipps-University Marburg, Germany. 3. Psychologische Hochschule, Berlin, Germany. 4. Department of Neurosurgery, University Medical Center, Göttingen, Germany. 5. Institute of Neuropathology, University Medical Center, Göttingen, Germany.
Abstract
STUDY OBJECTIVES: To investigate the development of REM sleep behavior disorder (RBD) and REM sleep behavioral events (RBE) not yet fulfilling diagnostic criteria for RBD as markers for neurodegeneration in a cohort of Parkinson disease (PD) patients between their de novo baseline assessment and two-year follow-up in comparison to healthy controls (HC). METHODS: Clinically confirmed PD patients and HC with video-supported polysomnography (vPSG) data at baseline were re-investigated after two years. Diagnostic scoring for RBE and RBD was performed in both groups and related to baseline findings. RESULTS: One hundred thirteen PD patients and 102 healthy controls (HC) were included in the study. Within two years, the overall occurrence of behaviors during REM sleep in PD patients increased from 50% to 63% (P = 0.02). RBD increased from 25% to 43% (P < 0.001). Eleven of 29 (38%) RBE positive PD patients and 10/56 (18%) patients with normal REM sleep at baseline converted to RBD. In HC, the occurrence of any REM behavior increased from 17% to 20% (n.s.). RBD increased from 2% to 4% (n.s.). One of 15 (7%) RBE positive HC and 1/85 (1%) HC with normal REM at baseline converted to RBD. CONCLUSIONS: RBD increased significantly in PD patients from the de novo state to two-year follow-up. We propose RBE being named "prodromal RBD" as it may follow a continuous evolution in PD possibly similar to the spreading of Lewy bodies in PD patients. RBD itself was shown as a robust and stable marker of early PD.
STUDY OBJECTIVES: To investigate the development of REM sleep behavior disorder (RBD) and REM sleep behavioral events (RBE) not yet fulfilling diagnostic criteria for RBD as markers for neurodegeneration in a cohort of Parkinson disease (PD) patients between their de novo baseline assessment and two-year follow-up in comparison to healthy controls (HC). METHODS: Clinically confirmed PDpatients and HC with video-supported polysomnography (vPSG) data at baseline were re-investigated after two years. Diagnostic scoring for RBE and RBD was performed in both groups and related to baseline findings. RESULTS: One hundred thirteen PDpatients and 102 healthy controls (HC) were included in the study. Within two years, the overall occurrence of behaviors during REM sleep in PDpatients increased from 50% to 63% (P = 0.02). RBD increased from 25% to 43% (P < 0.001). Eleven of 29 (38%) RBE positive PDpatients and 10/56 (18%) patients with normal REM sleep at baseline converted to RBD. In HC, the occurrence of any REM behavior increased from 17% to 20% (n.s.). RBD increased from 2% to 4% (n.s.). One of 15 (7%) RBE positive HC and 1/85 (1%) HC with normal REM at baseline converted to RBD. CONCLUSIONS: RBD increased significantly in PDpatients from the de novo state to two-year follow-up. We propose RBE being named "prodromal RBD" as it may follow a continuous evolution in PD possibly similar to the spreading of Lewy bodies in PDpatients. RBD itself was shown as a robust and stable marker of early PD.
Authors: B F Boeve; M H Silber; T J Ferman; S C Lin; E E Benarroch; A M Schmeichel; J E Ahlskog; R J Caselli; S Jacobson; M Sabbagh; C Adler; B Woodruff; T G Beach; A Iranzo; E Gelpi; J Santamaria; E Tolosa; C Singer; D C Mash; C Luca; I Arnulf; C Duyckaerts; C H Schenck; M W Mahowald; Y Dauvilliers; N R Graff-Radford; Z K Wszolek; J E Parisi; B Dugger; M E Murray; D W Dickson Journal: Sleep Med Date: 2013-03-07 Impact factor: 3.492
Authors: Julius B M Anang; Jean-Francois Gagnon; Josie-Anne Bertrand; Silvia Rios Romenets; Veronique Latreille; Michel Panisset; Jacques Montplaisir; Ronald B Postuma Journal: Neurology Date: 2014-08-29 Impact factor: 9.910
Authors: Alex Iranzo; Eduard Tolosa; Ellen Gelpi; José Luis Molinuevo; Francesc Valldeoriola; Mónica Serradell; Raquel Sanchez-Valle; Isabel Vilaseca; Francisco Lomeña; Dolores Vilas; Albert Lladó; Carles Gaig; Joan Santamaria Journal: Lancet Neurol Date: 2013-04-03 Impact factor: 44.182
Authors: Alex Iranzo; Ana Fernández-Arcos; Eduard Tolosa; Mónica Serradell; José Luis Molinuevo; Francesc Valldeoriola; Ellen Gelpi; Isabel Vilaseca; Raquel Sánchez-Valle; Albert Lladó; Carles Gaig; Joan Santamaría Journal: PLoS One Date: 2014-02-26 Impact factor: 3.240
Authors: John C Feemster; Youngsin Jung; Paul C Timm; Sarah M Westerland; Thomas R Gossard; Luke N Teigen; Lauren A Buchal; Elena F D Cattaneo; Charlotte A Imlach; Stuart J Mccarter; Kevin L Smith; Bradley F Boeve; Michael H Silber; Erik K St Louis Journal: Sleep Date: 2019-10-09 Impact factor: 5.849
Authors: Ambra Stefani; Anna Heidbreder; Elisabeth Brandauer; Marc Guaita; Lisa-Marie Neier; Thomas Mitterling; Joan Santamaria; Alex Iranzo; Aleksander Videnovic; Claudia Trenkwalder; Friederike Sixel-Döring; Gregor K Wenning; Anabel Chade; Werner Poewe; Oscar S Gershanik; Birgit Högl Journal: Sleep Date: 2018-06-01 Impact factor: 5.849